{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-25-000097","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.573503+00:00","generated_at":"2026-05-22T05:00:12.719354+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pliant Therapeutics Q1 net loss $56.2M, cuts workforce 45% to extend cash runway","bullets":["Net loss of $56.2M in Q1 2025 vs $47.0M prior-year; R&D expenses rose to $43.4M on BEACON-IPF close-out.","Announced ~45% workforce reduction on May 1, 2025, expected to be substantially completed by Q2 2025.","Cash, cash equivalents and short-term investments totaled $307.1M as of March 31, 2025.","BEACON-IPF topline data expected in Q2 2025; close-out activities ongoing.","Interim Phase 1 data for PLN-101095 plus pembrolizumab showed three confirmed partial responses in six patients at highest dose."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-25-000097","json":"https://secwatch.observer/filing/0001746473-25-000097.json","markdown":"https://secwatch.observer/filing/0001746473-25-000097.md","text":"https://secwatch.observer/filing/0001746473-25-000097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647325000097/0001746473-25-000097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647325000097/plrx-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:00:12.719354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}